News

Future of Batteries Summit 2025 to Accelerate US Energy Transition and Solid-State Battery Manufacturing
NEW YORK CITY, NEW YORK / ACCESS Newswire / June 14, 2025 / New to The Street (NTTS) and High Performance Battery Technology ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
BioPharma Dive1d
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
MedPage Today1d
U.K.: Toss Candy Over Cancer Risk; Ban TV Pharma Ads? 'Our Brains Stopped Working'
Note that some links may require registration or subscription. The United Kingdom's Food Standards Agency says that certain ...
Moderna falls on doubts over new CDC panel's backing of RSV vaccine
The mRNA-based RSV shot, mRESVIA, secured U.S. approval on Thursday for use in at-risk adults aged 18 to 59 years, but needs ...
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
FDA expands Moderna's RSV vaccine approval to at-risk adults
The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 ...
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up
The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
EconoTimes1d
FDA Expands Moderna’s RSV Vaccine Use to At-Risk Adults Aged 18–59
The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults ...
Amaze Announces Annual Stockholders’ Meeting Results and 1-for-23 Reverse Stock Split
NEWPORT BEACH, CA / ACCESS Newswire / June 12, 2025 / Amaze Holdings, Inc. (NYSE American:AMZE) (“Amaze” or the “Company”),a ...